See the DrugPatentWatch profile for Strensiq
What biosimilar could replace Strensiq (asfotase alfa), and is there one approved yet?
Strensiq is a brand of asfotase alfa, an enzyme replacement therapy used for hypophosphatasia (HPP). A “Strensiq biosimilar” would mean a product designed to match asfotase alfa’s active substance and clinical performance. With the provided information, there are no details confirming any specific asfotase alfa biosimilar’s approval status or availability.
What counts as a “biosimilar” versus a similar biologic drug?
For biologics like asfotase alfa, a biosimilar is evaluated to show it is highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency. A different “similar biologic” (sometimes called a follow-on biologic) may not have the same evidence package as a regulator-approved biosimilar, depending on the country’s approval pathway.
How would switching from Strensiq to a biosimilar work in practice?
If an asfotase alfa biosimilar becomes available and is approved in a patient’s country, switching typically depends on:
- Regulatory approval in that jurisdiction.
- Prescriber judgment and clinical factors (response history, tolerance, disease severity).
- Payer/coverage rules and pharmacy substitution policies.
- Ongoing monitoring for efficacy and side effects after the switch.
Where patients usually look for “Strensiq biosimilar” information
People searching for a Strensiq biosimilar often want:
- The product name (and which regulator approved it).
- The country or region where it is marketed.
- Expected dosing and whether it’s truly interchangeable.
- Cost and insurance coverage differences versus Strensiq.
- Safety/efficacy data and any immunogenicity findings.
What you can do next to get a concrete answer for your country
Tell me your country (or the market you’re in) and whether you mean:
1) an FDA/EMA-style biosimilar, or
2) any follow-on version of asfotase alfa,
and I can narrow to the specific product(s) that match your location and the regulatory category you care about.
Sources: none (the provided information did not include details about any specific Strensiq biosimilar).